NYSEAMERICAN:KAPA Kairos Pharma Q3 2025 Earnings Report $0.48 -0.01 (-2.05%) Closing price 05/15/2026 04:10 PM EasternExtended Trading$0.50 +0.01 (+2.65%) As of 05/15/2026 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kairos Pharma EPS ResultsActual EPS-$0.07Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AKairos Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKairos Pharma Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 14, 2025Conference Call Time7:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Kairos Pharma Earnings HeadlinesKairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual FilingsMay 8, 2026 | businesswire.comKAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation with the Schall Law FirmApril 28, 2026 | globenewswire.com5 steps to bulletproof every tradeMost traders skip a critical step before entering a position - and it costs them. The Safe Trade Options Formula is a free 5-part framework built to help you evaluate every trade before you place it. The formula covers five straightforward steps designed to filter out risky setups and give you a more disciplined approach to options trading.May 16 at 1:00 AM | Profits Run (Ad)Kairos Pharma (KAPA) price target decreased by 14.29% to 9.18April 15, 2026 | msn.comKairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPAApril 12, 2026 | businesswire.comRosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPAApril 11, 2026 | businesswire.comSee More Kairos Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kairos Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kairos Pharma and other key companies, straight to your email. Email Address About Kairos PharmaKairos Pharma (NYSEAMERICAN:KAPA) (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications. Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics. The company collaborates with academic institutions and patient advocacy groups to advance its programs through clinical milestones and facilitate patient access. By concentrating on precision modulation of the translational machinery, Kairos Pharma aims to address diseases with high unmet medical need and no currently approved treatments. Governed by an experienced leadership team with backgrounds in drug development, regulatory affairs and commercial strategy, Kairos Pharma maintains research operations in the United States and Europe. The company continues to forge strategic partnerships and secure financing to support its development programs and expand its pipeline. With a science‐driven approach and commitment to rare disease communities, Kairos Pharma is positioned to deliver innovative therapies to patients worldwide.View Kairos Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavalut Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying OpportunityCisco’s Vertical Rally May Still Be in the Early Innings Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
